Steatosis Drives Liver Metastasis Heterogeneity in CRC

Liver steatosis, commonly known as fatty liver disease, significantly shapes the heterogeneity of liver metastases in colorectal cancer (CRC), influencing patient prognosis. Research published online in Nature on July 1, 2026, details the molecular mechanisms by which steatosis promotes the formation of replacement liver metastases.

The study found that liver steatosis increases the stability of the MYC protein through acetylation. This enhanced MYC stability, in turn, drives an increase in proline synthesis and collagen production within the liver microenvironment. These biochemical changes create a more conducive environment for the growth and spread of cancer cells, leading to the development of replacement liver metastases.

This mechanism highlights a critical link between metabolic health, specifically liver fat accumulation, and the aggressive progression of colorectal cancer. The findings suggest that the presence and severity of liver steatosis could serve as a prognostic marker for CRC patients, indicating a higher likelihood of developing more aggressive and treatment-resistant liver metastases. Understanding this interplay is crucial for developing targeted therapeutic strategies aimed at improving outcomes for CRC patients.